Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASTE-A: Tenecteplase vs Alteplase in Mobile Stroke Unit
NCT04071613Phase 2Completed
- Sponsor
- Melbourne Health
- Start
- Jun 2019
- Primary completion
- Nov 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of tenecteplase in ischemic stroke, sponsored by Melbourne Health. Primary endpoint: Perfusion lesion on CTP at 2 hours. Started Jun 2019; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04071613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071613.